Incidence of prostate cancer after termination of screening in a population-based randomised screening trial.

Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data. J Natl Cancer Inst (2014) 3.19

Expected population impacts of discontinued prostate-specific antigen screening. Cancer (2014) 1.24

Prostate cancer boost using high-dose-rate brachytherapy: early toxicity analysis of 3 different fractionation schemes. J Contemp Brachytherapy (2013) 0.81

An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol (2015) 0.81

The Effect of Start and Stop Age at Screening on the Risk of Being Diagnosed with Prostate Cancer. J Urol (2015) 0.78

Prostate cancer screening in Brazil: should it be done or not? Int Braz J Urol (2016) 0.75

Prostate-specific antigen-based screening for prostate cancer: the irony of it all. Eur Urol (2013) 0.75

Prostate cancer: the growing evidence supporting mid-life PSA testing. Nat Rev Urol (2013) 0.75

Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94

Prostate-cancer mortality at 11 years of follow-up. N Engl J Med (2012) 16.91

Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol (2010) 12.64

Quality-of-life effects of prostate-specific antigen screening. N Engl J Med (2012) 7.21

HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol (2009) 4.99

Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol (2012) 4.07

Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol (2009) 3.42

Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam. J Natl Cancer Inst (2007) 3.26

Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. Radiat Res (2002) 3.07

Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol (2008) 2.92

The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res (2010) 2.87

Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial. Eur Urol (2012) 2.79

Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. BMJ (2014) 2.61

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. BMC Med (2008) 2.47

Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst (2010) 2.45

Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol (2009) 2.31

The Study of Active Monitoring in Sweden (SAMS): a randomized study comparing two different follow-up schedules for active surveillance of low-risk prostate cancer. Scand J Urol (2013) 2.29

PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer (2007) 2.27

Surveillance and deferred treatment for localized prostate cancer. Population based study in the National Prostate Cancer Register of Sweden. J Urol (2008) 2.17

Prostate cancer mortality in areas with high and low prostate cancer incidence. J Natl Cancer Inst (2014) 2.16

The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Cancer (2010) 2.15

Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C. Clin Chem (2005) 2.05

Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. Eur Urol (2012) 1.96

Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial. Eur Urol (2006) 1.94

No excess mortality after prostate biopsy: results from the European Randomized Study of Screening for Prostate Cancer. BJU Int (2010) 1.94

Lead time associated with screening for prostate cancer. Int J Cancer (2004) 1.93

Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol (2007) 1.93

Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int J Cancer (2002) 1.89

Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. J Clin Oncol (2012) 1.82

Outcome of primary versus deferred radical prostatectomy in the National Prostate Cancer Register of Sweden Follow-Up Study. J Urol (2010) 1.75

Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. BJU Int (2004) 1.68

Psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: cross sectional questionnaire study. BMJ (2004) 1.60

Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. Proc Natl Acad Sci U S A (2010) 1.59

Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. Arch Intern Med (2005) 1.57

Symptoms 10-17 years after breast cancer radiotherapy data from the randomised SWEBCG91-RT trial. Radiother Oncol (2010) 1.50

The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. J Med Screen (2012) 1.46

Radical prostatectomy versus high-dose irradiation in localized/locally advanced prostate cancer: A Swedish multicenter randomized trial with patient-reported outcomes. Acta Oncol (2014) 1.46

Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol (2011) 1.42

Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis. Eur J Haematol (2014) 1.42

Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk? BJU Int (2013) 1.39

Premenopausal mammographic density in relation to cyclic variations in endogenous sex hormone levels, prolactin, and insulin-like growth factors. Cancer Res (2009) 1.35

Anxiety associated with prostate cancer screening with special reference to men with a positive screening test (elevated PSA) - Results from a prospective, population-based, randomised study. Eur J Cancer (2007) 1.35

Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden. Cancer (2010) 1.35

A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer (2011) 1.34

Risk of dying from prostate cancer in men randomized to screening: differences between attendees and nonattendees. Cancer (2009) 1.32

Lifetime effects, costs, and cost effectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: results of the NHS pilot studies. BMJ (2006) 1.28

Towards an optimal interval for prostate cancer screening. Eur Urol (2011) 1.27

Non-systematic screening for prostate cancer in Sweden--survey from the National Prostate Cancer Registry. Scand J Urol Nephrol (2003) 1.20

The excess burden of side-effects from treatment in men allocated to screening for prostate cancer. The Göteborg randomised population-based prostate cancer screening trial. Eur J Cancer (2010) 1.20

The National Prostate Cancer Register in Sweden 1998-2002: trends in incidence, treatment and survival. Scand J Urol Nephrol (2005) 1.20

Post-radical prostatectomy inguinal hernia: a simple surgical intervention can substantially reduce the incidence--results from a prospective randomized trial. J Urol (2010) 1.19

Post-radical retropubic prostatectomy inguinal hernia: an analysis of risk factors with special reference to preoperative inguinal hernia morbidity and pelvic lymph node dissection. J Urol (2006) 1.18

The effect of mammographic screening and hormone replacement therapy use on breast cancer incidence in England and Wales. Cancer Epidemiol Biomarkers Prev (2007) 1.15

Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes? Cancer (2010) 1.13

Lead-time in the European Randomised Study of Screening for Prostate Cancer. Eur J Cancer (2010) 1.13

The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable. J Urol (2004) 1.12

Standardization of Gleason grading among 337 European pathologists. Histopathology (2013) 1.09

Breast cancer mortality in mammographic screening in Europe: a review of incidence-based mortality studies. J Med Screen (2012) 1.08

Treatment for high-risk smoldering myeloma. N Engl J Med (2013) 1.08

Does initial surveillance in early prostate cancer reduce the chance of cure by radical prostatectomy?--A case control study. Scand J Urol Nephrol (2003) 1.07

Four-hundredfold overestimation of biopsy mortality. BJU Int (2013) 1.07

High accuracy of Swedish death certificates in men participating in screening for prostate cancer: a comparative study of official death certificates with a cause of death committee using a standardized algorithm. Scand J Urol Nephrol (2011) 1.06

A pooled analysis of thyroid cancer incidence following radiotherapy for childhood cancer. Radiat Res (2012) 1.03

The impact of birth weight on prostate cancer incidence and mortality in a population-based study of men born in 1913 and followed up from 50 to 85 years of age. Prostate (2007) 1.02

False-positive screening results in the European randomized study of screening for prostate cancer. Eur J Cancer (2011) 1.02

Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. World J Urol (2011) 1.00

Increase in percent free prostate-specific antigen in men with chronic kidney disease. Nephrol Dial Transplant (2008) 1.00

Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group. Eur J Cancer (2011) 0.97

A population-based 5-year cohort study including all cases of epithelial ovarian cancer in western Sweden: 10-year survival and prognostic factors. Int J Gynecol Cancer (2009) 0.96

Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men. BJU Int (2009) 0.94

Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol (2012) 0.94

Cost effectiveness of human papillomavirus test of cure after treatment for cervical intraepithelial neoplasia in England: economic analysis from NHS Sentinel Sites Study. BMJ (2012) 0.94

Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy. Scand J Urol Nephrol (2009) 0.93

Inguinal hernia in stage M0 prostate cancer: a comparison of incidence in men treated with and without radical retropubic prostatectomy--an analysis of 1105 patients. Urology (2005) 0.93

LAPPRO: a prospective multicentre comparative study of robot-assisted laparoscopic and retropubic radical prostatectomy for prostate cancer. Scand J Urol Nephrol (2010) 0.92

Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial. J Med Screen (2013) 0.92

Leukaemia incidence in people living close to an oil refinery. Environ Res (2009) 0.91

Nationwide population-based study on 30-day mortality after radical prostatectomy in Sweden. Scand J Urol Nephrol (2009) 0.91

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. Eur J Haematol (2012) 0.91

Automation-assisted versus manual reading of cervical cytology (MAVARIC): a randomised controlled trial. Lancet Oncol (2010) 0.90

Long-term symptoms after radiotherapy of supraclavicular lymph nodes in breast cancer patients. Radiother Oncol (2012) 0.89

Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone. Cancer (2008) 0.89

Detection rates of high-grade prostate cancer during subsequent screening visits. Results of the European Randomized Screening Study for Prostate Cancer. Int J Cancer (2006) 0.89

Efficacy versus effectiveness study design within the European screening trial for prostate cancer: consequences for cancer incidence, overall mortality and cancer-specific mortality. J Med Screen (2012) 0.89

The absence of voiding symptoms in men with a prostate-specific antigen (PSA) concentration of ≥3.0 ng/mL is an independent risk factor for prostate cancer: results from the Gothenburg Randomized Screening Trial. BJU Int (2012) 0.89

Kidney cancer in Sweden: a decrease in incidence and tumour stage, 1979 - 2001. Scand J Urol (2012) 0.89

Cancer incidence in a petrochemical industry area in Sweden. Sci Total Environ (2010) 0.88

Test sensitivity in the European prostate cancer screening trial: results from Finland, Sweden, and the Netherlands. Cancer Epidemiol Biomarkers Prev (2009) 0.87